Skip to main content
. 2012 Nov 1;6(2):467–478. doi: 10.1242/dmm.010520

Fig. 4.

Fig. 4.

2CA attenuates demyelinating disease in ND4 mice. (A) ND4 mice treated with PBS, 2CA (5 mg/kg), or 2CA+B12 (5 mg/kg and 10 mg/kg) starting at 2 months before disease onset (n=5, P<0.0001). (B) ND4 mice treated at disease onset (n=4, P<0.0001). (C) Stopping 2CA, but continuing B12 at 3.5 months in ND4 mice (n=5, P<0.0001) demonstrates that B12 alone does not attenuate disease. (D) PAD activity in brains from animals shown in Fig. 3B (n=5, P<0.05). The first four bars represent results from animals at 6 months of age, whereas the post-treatment animals were 8 months of age. (E) PAD2 RT PCR in white matter extracts from normal, PBS-, 2CA- and 2CA+B12-treated ND4 mice (n=9, P<0.05). (F) LFB and hematoxylin stain of cerebella from normal, PBS-, 2CA- and 2CA+B12-treated ND4 mice (40×). WM, white matter; GM, grey matter.